QLS-215

Astria Therapeutics has initiated a pivotal Phase III clinical trial evaluating STAR-0215, a novel monoclonal antibody therapy for hereditary angioedema prevention.

Intellia Therapeutics has initiated Phase 3 trials for NTLA-2002, a groundbreaking CRISPR-based gene therapy for hereditary angioedema, with potential U.S. launch targeted for 2027.

Interim analysis of the ALPHA-STAR trial demonstrates navenibart's effectiveness in reducing hereditary angioedema attacks, with complete elimination of severe attacks at both 3- and 6-month follow-ups.

Astria Therapeutics is initiating the ALPHA-ORBIT Phase 3 trial to evaluate navenibart for hereditary angioedema (HAE) with flexible dosing.

Astria Therapeutics' navenibart demonstrated a 90-95% reduction in mean monthly attack rates in HAE patients over six months.